WOODCLIFF LAKE, N.J., April 18, 2012 /PRNewswire/ -- Eisai Inc. announced today that the results of the study, "Randomized Phase III Study 306: Adjunctive Perampanel for Refractory Partial-Onset Seizures," were published online today in the April 18, 2012, edition of Neurology®.
(Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO)
Marketing authorization applications for perampanel are currently under review with the U.S. Food and Drug Administration and the European Medicines Agency.
About Perampanel
Perampanel is an orally administered, highly selective non-competitive AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)-type glutamate receptor antagonist, discovered and being developed by Eisai.
About Eisai Inc.
Eisai Inc. was established in 1995 and began marketing its first product in the United States in 1997. Since that time, Eisai Inc. has rapidly grown to become a fully integrated pharmaceutical business. Eisai's key areas of commercial focus are neurology and oncology. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.
Eisai has a global product creation organization that includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com/US.
About Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. Eisai employs approximately 11,000 employees worldwide.
SOURCE Eisai Inc.
Photo:http://photos.prnewswire.com/prnh/20120413/MM87168LOGO
http://photoarchive.ap.org/
SOURCE: Eisai Inc.
PR Newswire
WOODCLIFF LAKE, N.J., April 18, 2012
WOODCLIFF LAKE, N.J., April 18, 2012 /PRNewswire/ -- Eisai Inc. announced today that the results of the study, "Randomized Phase III Study 306: Adjunctive Perampanel for Refractory Partial-Onset Seizures," were published online today in the April 18, 2012, edition of Neurology®.
(Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO)
Marketing authorization applications for perampanel are currently under review with the U.S. Food and Drug Administration and the European Medicines Agency.
About Perampanel
Perampanel is an orally administered, highly selective non-competitive AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)-type glutamate receptor antagonist, discovered and being developed by Eisai.
About Eisai Inc.
Eisai Inc. was established in 1995 and began marketing its first product in the United States in 1997. Since that time, Eisai Inc. has rapidly grown to become a fully integrated pharmaceutical business. Eisai's key areas of commercial focus are neurology and oncology. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.
Eisai has a global product creation organization that includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com/US.
About Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. Eisai employs approximately 11,000 employees worldwide.
SOURCE Eisai Inc.
CONTACT: Media Inquiries: Marcia J. Diljak, Eisai Inc., +1-201-746-2236; Investor Inquiries: Alex Scott, Eisai Inc., +1-201-746-2177
Web Site: http://www.eisai.com
Type Press Release
Date Released April 18, 2012